Licensing status

Publication and contact information

Infectious disease


Ebola glycoprotein GP1

Studies in primates suggest rabies (RABV)-based vaccine vectors expressing GP1 could be used to prevent Ebola infection. In macaques immunized with replication-competent, replication-deficient or inactivated RABV-GP1 vaccines, neutralizing antibodies against both GP1 and RABV glycoproteins were detected. In immunized macaques challenged with Ebola virus, the replication-competent vaccine protected 100% of the primates, whereas the replication-deficient and inactivated vaccines protected about 50% of the primates. Next steps could include optimizing a prime-boost vaccine strategy.

SciBX 6(26); doi:10.1038/scibx.2013.657
Published online July 11, 2013

Patented; available for licensing from the NIH Office of Acquisition Management and Policy
Contact: Peter Soukas, National Institutes of Health, Bethesda, Md.

Blaney, J.E. et al. PLoS Pathog.; published online May 30, 2013;
Contact: Matthias J. Schnell, Thomas Jefferson University, Philadelphia, Pa.